Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models
Sign Up to like & getrecommendations! Published in 2022 at "Circulation"
DOI: 10.1161/circulationaha.122.062132
Abstract: Background: VERVE-101 is an investigational in vivo CRISPR base-editing medicine designed to alter a single DNA base in the PCSK9 gene, permanently turn off hepatic protein production, and thereby durably lower low-density lipoprotein cholesterol. We… read more here.
Keywords: verve; verve 101; pcsk9; crispr base ... See more keywords